Overview

Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

Status:
Completed
Trial end date:
2017-04-07
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the incidence of diabetic ketoacidosis (DKA) among participants diagnosed with type 2 diabetes mellitus (T2DM) and pair-matched on exposure propensity scores for new use of any sodium-glucose co-transporter 2 inhibitors (SGLT2i) versus new use of various other antihyperglycemic agents (AHAs), combined as one group.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Hypoglycemic Agents
Criteria
Inclusion Criteria:

- At least 1 antihyperglycemic agents (AHA) prescription (Rx) during the study period,
between 4/1/2013 and 9/30/2014.

- Diagnosed of type 2 diabetes mellitus

- Enrollment history of at least 12 months

- Having prescription drug coverage

- Having no prescription of the index drug during the 6 months prior

Exclusion Criteria:

- Participants who receive diagnosis of type1 diabetes mellitus (T1DM) and/or secondary
diabetes mellitus (SDM) any time after index date.